7:33 PM
 | 
Nov 16, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

CHMP recommends Amgen's Avastin biosimilar ABP 215

EMA's CHMP recommended approval of ABP 215 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Avastin bevacizumab, for all cancer types on Avastin's EU label: non-small cell lung cancer (NSCLC),...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >